JP2005516006A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005516006A5 JP2005516006A5 JP2003550790A JP2003550790A JP2005516006A5 JP 2005516006 A5 JP2005516006 A5 JP 2005516006A5 JP 2003550790 A JP2003550790 A JP 2003550790A JP 2003550790 A JP2003550790 A JP 2003550790A JP 2005516006 A5 JP2005516006 A5 JP 2005516006A5
- Authority
- JP
- Japan
- Prior art keywords
- benzothiazol
- methoxy
- morpholin
- aza
- amide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 24
- 125000000217 alkyl group Chemical group 0.000 claims 16
- -1 tetrahydropyran-4-yl Chemical group 0.000 claims 7
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 5
- 239000002253 acid Substances 0.000 claims 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- KYCAEEFYFFBAAP-UHFFFAOYSA-N 1,4-diazabicyclo[3.2.1]octane Chemical compound C1C2CCN1CCN2 KYCAEEFYFFBAAP-UHFFFAOYSA-N 0.000 claims 3
- KVYOWXUQJLOCIA-UHFFFAOYSA-N 1-oxa-8-azaspiro[4.5]decane Chemical compound C1CCOC21CCNCC2 KVYOWXUQJLOCIA-UHFFFAOYSA-N 0.000 claims 3
- HHIOFHJYOIVJJK-UHFFFAOYSA-N 2,8-diazaspiro[4.5]decan-1-one Chemical compound O=C1NCCC11CCNCC1 HHIOFHJYOIVJJK-UHFFFAOYSA-N 0.000 claims 3
- DIQOUXNTSMWQSA-UHFFFAOYSA-N 2-oxa-5-azabicyclo[2.2.1]heptane Chemical compound C1OC2CNC1C2 DIQOUXNTSMWQSA-UHFFFAOYSA-N 0.000 claims 3
- JNYWVERKQKRXSL-UHFFFAOYSA-N 2-oxa-5-azabicyclo[2.2.2]octane Chemical compound C1NC2CCC1OC2 JNYWVERKQKRXSL-UHFFFAOYSA-N 0.000 claims 3
- GYLMCBOAXJVARF-UHFFFAOYSA-N 3-azabicyclo[2.2.1]heptane Chemical compound C1C2CCC1NC2 GYLMCBOAXJVARF-UHFFFAOYSA-N 0.000 claims 3
- KPUSZZFAYGWAHZ-UHFFFAOYSA-N 3-azabicyclo[2.2.2]octane Chemical compound C1CC2CCC1NC2 KPUSZZFAYGWAHZ-UHFFFAOYSA-N 0.000 claims 3
- CJQNJRRDTPULTL-UHFFFAOYSA-N 3-azabicyclo[3.2.1]octane Chemical compound C1C2CCC1CNC2 CJQNJRRDTPULTL-UHFFFAOYSA-N 0.000 claims 3
- LIZKZVQBLDHKCY-UHFFFAOYSA-N 3-azaspiro[5.5]undecane Chemical compound C1CCCCC21CCNCC2 LIZKZVQBLDHKCY-UHFFFAOYSA-N 0.000 claims 3
- CHRAJVQLWOMYQI-UHFFFAOYSA-N 5,8,8-trimethyl-3-azabicyclo[3.2.1]octane Chemical compound C1NCC2CCC1(C)C2(C)C CHRAJVQLWOMYQI-UHFFFAOYSA-N 0.000 claims 3
- POOPWPIOIMBTOH-UHFFFAOYSA-N 8-oxa-3-azabicyclo[3.2.1]octane Chemical compound C1NCC2CCC1O2 POOPWPIOIMBTOH-UHFFFAOYSA-N 0.000 claims 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 3
- YYMCYJLIYNNOMK-UHFFFAOYSA-N N-normethyltropine Natural products C1C(O)CC2CCC1N2 YYMCYJLIYNNOMK-UHFFFAOYSA-N 0.000 claims 3
- AXMNGEUJXLXFRY-UHFFFAOYSA-N azaspirodecane Chemical compound C1CCCC21CCNCC2 AXMNGEUJXLXFRY-UHFFFAOYSA-N 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- FLBNPQJRBGWRKR-UHFFFAOYSA-N 4-(methanesulfonamidomethyl)-n-(4-methoxy-7-morpholin-4-yl-1,3-benzothiazol-2-yl)piperidine-1-carboxamide Chemical compound C1=2SC(NC(=O)N3CCC(CNS(C)(=O)=O)CC3)=NC=2C(OC)=CC=C1N1CCOCC1 FLBNPQJRBGWRKR-UHFFFAOYSA-N 0.000 claims 2
- IFCMUPMBYYVMGO-CYBMUJFWSA-N 4-[(1r)-1-hydroxyethyl]-n-(4-methoxy-7-morpholin-4-yl-1,3-benzothiazol-2-yl)piperidine-1-carboxamide Chemical compound C1=2SC(NC(=O)N3CCC(CC3)[C@@H](C)O)=NC=2C(OC)=CC=C1N1CCOCC1 IFCMUPMBYYVMGO-CYBMUJFWSA-N 0.000 claims 2
- IFCMUPMBYYVMGO-ZDUSSCGKSA-N 4-[(1s)-1-hydroxyethyl]-n-(4-methoxy-7-morpholin-4-yl-1,3-benzothiazol-2-yl)piperidine-1-carboxamide Chemical compound C1=2SC(NC(=O)N3CCC(CC3)[C@H](C)O)=NC=2C(OC)=CC=C1N1CCOCC1 IFCMUPMBYYVMGO-ZDUSSCGKSA-N 0.000 claims 2
- HIONBFAFOGSFGW-UHFFFAOYSA-N 4-benzyl-4-(hydroxymethyl)-n-(4-methoxy-7-morpholin-4-yl-1,3-benzothiazol-2-yl)piperidine-1-carboxamide Chemical compound C1=2SC(NC(=O)N3CCC(CO)(CC=4C=CC=CC=4)CC3)=NC=2C(OC)=CC=C1N1CCOCC1 HIONBFAFOGSFGW-UHFFFAOYSA-N 0.000 claims 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims 2
- QFLBKCIGHQIBLY-HDJSIYSDSA-N C1=2SC(NC(=O)N(C)[C@@H]3CC[C@@H](O)CC3)=NC=2C(OC)=CC=C1N1CCOCC1 Chemical compound C1=2SC(NC(=O)N(C)[C@@H]3CC[C@@H](O)CC3)=NC=2C(OC)=CC=C1N1CCOCC1 QFLBKCIGHQIBLY-HDJSIYSDSA-N 0.000 claims 2
- QFLBKCIGHQIBLY-OKILXGFUSA-N C1=2SC(NC(=O)N(C)[C@H]3CC[C@@H](O)CC3)=NC=2C(OC)=CC=C1N1CCOCC1 Chemical compound C1=2SC(NC(=O)N(C)[C@H]3CC[C@@H](O)CC3)=NC=2C(OC)=CC=C1N1CCOCC1 QFLBKCIGHQIBLY-OKILXGFUSA-N 0.000 claims 2
- QUYUZBGIPLRICV-GASCZTMLSA-N C1C[C@@H](OC)CC[C@H]1N(C)C(=O)NC1=NC2=C(OC)C=CC(N3CCOCC3)=C2S1 Chemical compound C1C[C@@H](OC)CC[C@H]1N(C)C(=O)NC1=NC2=C(OC)C=CC(N3CCOCC3)=C2S1 QUYUZBGIPLRICV-GASCZTMLSA-N 0.000 claims 2
- 229960005305 adenosine Drugs 0.000 claims 2
- 150000001408 amides Chemical class 0.000 claims 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- WJJHANCJJOEBQD-UHFFFAOYSA-N n-(4-chloro-7-piperidin-1-yl-1,3-benzothiazol-2-yl)-4-hydroxy-4-[(4-methylphenyl)methyl]piperidine-1-carboxamide Chemical compound C1=CC(C)=CC=C1CC1(O)CCN(C(=O)NC=2SC3=C(N4CCCCC4)C=CC(Cl)=C3N=2)CC1 WJJHANCJJOEBQD-UHFFFAOYSA-N 0.000 claims 2
- IYFPKFFZLUBDGN-UHFFFAOYSA-N n-(4-methoxy-7-morpholin-4-yl-1,3-benzothiazol-2-yl)-1-oxa-8-azaspiro[4.5]decane-8-carboxamide Chemical compound C1=2SC(NC(=O)N3CCC4(OCCC4)CC3)=NC=2C(OC)=CC=C1N1CCOCC1 IYFPKFFZLUBDGN-UHFFFAOYSA-N 0.000 claims 2
- AJUXKMMSLQDKII-UHFFFAOYSA-N n-(4-methoxy-7-morpholin-4-yl-1,3-benzothiazol-2-yl)-1-oxo-2,8-diazaspiro[4.5]decane-8-carboxamide Chemical compound C1=2SC(NC(=O)N3CCC4(C(NCC4)=O)CC3)=NC=2C(OC)=CC=C1N1CCOCC1 AJUXKMMSLQDKII-UHFFFAOYSA-N 0.000 claims 2
- YSIZCVKNKKXRDX-UHFFFAOYSA-N n-(4-methoxy-7-morpholin-4-yl-1,3-benzothiazol-2-yl)-2-methyl-1-oxo-2,8-diazaspiro[4.5]decane-8-carboxamide Chemical compound C1=2SC(NC(=O)N3CCC4(C(N(C)CC4)=O)CC3)=NC=2C(OC)=CC=C1N1CCOCC1 YSIZCVKNKKXRDX-UHFFFAOYSA-N 0.000 claims 2
- HURFKWOYYGOEDL-UHFFFAOYSA-N n-(4-methoxy-7-morpholin-4-yl-1,3-benzothiazol-2-yl)-2-oxa-5-azabicyclo[2.2.2]octane-5-carboxamide Chemical compound C1=2SC(NC(=O)N3C4CCC(OC4)C3)=NC=2C(OC)=CC=C1N1CCOCC1 HURFKWOYYGOEDL-UHFFFAOYSA-N 0.000 claims 2
- YXKZXASPEPLXDA-UHFFFAOYSA-N n-(4-methoxy-7-morpholin-4-yl-1,3-benzothiazol-2-yl)-3-azabicyclo[2.2.2]octane-3-carboxamide Chemical compound C1=2SC(NC(=O)N3C4CCC(CC4)C3)=NC=2C(OC)=CC=C1N1CCOCC1 YXKZXASPEPLXDA-UHFFFAOYSA-N 0.000 claims 2
- NVJVAOWILSOJGP-UHFFFAOYSA-N n-(4-methoxy-7-morpholin-4-yl-1,3-benzothiazol-2-yl)-3-azaspiro[5.5]undecane-3-carboxamide Chemical compound C1=2SC(NC(=O)N3CCC4(CCCCC4)CC3)=NC=2C(OC)=CC=C1N1CCOCC1 NVJVAOWILSOJGP-UHFFFAOYSA-N 0.000 claims 2
- WOJYLKMRSKGFTI-UHFFFAOYSA-N n-(4-methoxy-7-morpholin-4-yl-1,3-benzothiazol-2-yl)-8-azaspiro[4.5]decane-8-carboxamide Chemical compound C1=2SC(NC(=O)N3CCC4(CCCC4)CC3)=NC=2C(OC)=CC=C1N1CCOCC1 WOJYLKMRSKGFTI-UHFFFAOYSA-N 0.000 claims 2
- LQTHHEQEIWKZGY-UHFFFAOYSA-N n-(4-methoxy-7-piperidin-1-yl-1,3-benzothiazol-2-yl)-1-oxa-8-azaspiro[4.5]decane-8-carboxamide Chemical compound C1=2SC(NC(=O)N3CCC4(OCCC4)CC3)=NC=2C(OC)=CC=C1N1CCCCC1 LQTHHEQEIWKZGY-UHFFFAOYSA-N 0.000 claims 2
- AQNQGBUEVCAVML-UHFFFAOYSA-N oxazepane Chemical compound C1CCNOCC1 AQNQGBUEVCAVML-UHFFFAOYSA-N 0.000 claims 2
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 2
- IIKFXOLJMNWWCH-UHFFFAOYSA-N piperidine-1,4-dicarboxylic acid Chemical compound OC(=O)C1CCN(C(O)=O)CC1 IIKFXOLJMNWWCH-UHFFFAOYSA-N 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 208000011117 substance-related disease Diseases 0.000 claims 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 1
- CKOFIRBMZAAFLM-OLZOCXBDSA-N (1r,4s)-n-(4-methoxy-7-morpholin-4-yl-1,3-benzothiazol-2-yl)-3-azabicyclo[2.2.1]heptane-3-carboxamide Chemical compound N1([C@@]2([H])CC[C@](C2)(C1)[H])C(=O)NC(SC1=2)=NC1=C(OC)C=CC=2N1CCOCC1 CKOFIRBMZAAFLM-OLZOCXBDSA-N 0.000 claims 1
- SSJXIUAHEKJCMH-WDSKDSINSA-N (1s,2s)-cyclohexane-1,2-diamine Chemical compound N[C@H]1CCCC[C@@H]1N SSJXIUAHEKJCMH-WDSKDSINSA-N 0.000 claims 1
- VGMHMYUFRKBDIS-WHFBIAKZSA-N (1s,4s)-2-oxa-5-azabicyclo[2.2.1]heptane-5-carboxylic acid Chemical compound C1[C@@H]2N(C(=O)O)C[C@H]1OC2 VGMHMYUFRKBDIS-WHFBIAKZSA-N 0.000 claims 1
- XBKJNVIPKGZBKC-RYUDHWBXSA-N (1s,4s)-n-(4-methoxy-7-morpholin-4-yl-1,3-benzothiazol-2-yl)-2-oxa-5-azabicyclo[2.2.1]heptane-5-carboxamide Chemical compound C([C@]1(OC[C@]2([H])C1)[H])N2C(=O)NC(SC1=2)=NC1=C(OC)C=CC=2N1CCOCC1 XBKJNVIPKGZBKC-RYUDHWBXSA-N 0.000 claims 1
- RXNXSFVNJXCUGB-LYNSQETBSA-N (5r)-5,8,8-trimethyl-3-azabicyclo[3.2.1]octane-3-carboxylic acid Chemical compound C1N(C(O)=O)C[C@]2(C)CCC1C2(C)C RXNXSFVNJXCUGB-LYNSQETBSA-N 0.000 claims 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 claims 1
- KZKRRZFCAYOXQE-UHFFFAOYSA-N 1$l^{2}-azinane Chemical group C1CC[N]CC1 KZKRRZFCAYOXQE-UHFFFAOYSA-N 0.000 claims 1
- ZNGWEEUXTBNKFR-UHFFFAOYSA-N 1,4-oxazepane Chemical compound C1CNCCOC1 ZNGWEEUXTBNKFR-UHFFFAOYSA-N 0.000 claims 1
- CYOQYWSVWLVUNQ-UHFFFAOYSA-N 1-(4,4-difluorocyclohexyl)-3-(4-methoxy-7-morpholin-4-yl-1,3-benzothiazol-2-yl)-1-methylurea Chemical compound C1=2SC(NC(=O)N(C)C3CCC(F)(F)CC3)=NC=2C(OC)=CC=C1N1CCOCC1 CYOQYWSVWLVUNQ-UHFFFAOYSA-N 0.000 claims 1
- QUYUZBGIPLRICV-UHFFFAOYSA-N 1-(4-methoxycyclohexyl)-3-(4-methoxy-7-morpholin-4-yl-1,3-benzothiazol-2-yl)-1-methylurea Chemical compound C1CC(OC)CCC1N(C)C(=O)NC1=NC2=C(OC)C=CC(N3CCOCC3)=C2S1 QUYUZBGIPLRICV-UHFFFAOYSA-N 0.000 claims 1
- NSGALPBZLUIXNP-UHFFFAOYSA-N 1-cycloheptyl-3-(4-methoxy-7-morpholin-4-yl-1,3-benzothiazol-2-yl)-1-methylurea Chemical compound C1=2SC(NC(=O)N(C)C3CCCCCC3)=NC=2C(OC)=CC=C1N1CCOCC1 NSGALPBZLUIXNP-UHFFFAOYSA-N 0.000 claims 1
- ZMZFUVWCTYCGGP-UHFFFAOYSA-N 1-cyclohexyl-3-(4-methoxy-7-morpholin-4-yl-1,3-benzothiazol-2-yl)-1-methylurea Chemical compound C1=2SC(NC(=O)N(C)C3CCCCC3)=NC=2C(OC)=CC=C1N1CCOCC1 ZMZFUVWCTYCGGP-UHFFFAOYSA-N 0.000 claims 1
- CATYLCHNNIEDLB-UHFFFAOYSA-N 1-cyclopentyl-3-(4-methoxy-7-morpholin-4-yl-1,3-benzothiazol-2-yl)-1-methylurea Chemical compound C1=2SC(NC(=O)N(C)C3CCCC3)=NC=2C(OC)=CC=C1N1CCOCC1 CATYLCHNNIEDLB-UHFFFAOYSA-N 0.000 claims 1
- FBWTZOLFAPRERY-UHFFFAOYSA-N 3-(4-methoxy-7-morpholin-4-yl-1,3-benzothiazol-2-yl)-1-methyl-1-(oxan-4-yl)urea Chemical compound C1=2SC(NC(=O)N(C)C3CCOCC3)=NC=2C(OC)=CC=C1N1CCOCC1 FBWTZOLFAPRERY-UHFFFAOYSA-N 0.000 claims 1
- YLHLDUAMNQPUTF-UHFFFAOYSA-N 4-benzyl-n-(4-chloro-7-piperidin-1-yl-1,3-benzothiazol-2-yl)piperidine-1-carboxamide Chemical compound C1=2SC(NC(=O)N3CCC(CC=4C=CC=CC=4)CC3)=NC=2C(Cl)=CC=C1N1CCCCC1 YLHLDUAMNQPUTF-UHFFFAOYSA-N 0.000 claims 1
- KQPHMMBVFBMPPA-UHFFFAOYSA-N 4-chloro-7-piperidin-1-yl-1,3-benzothiazol-2-amine Chemical compound C=12SC(N)=NC2=C(Cl)C=CC=1N1CCCCC1 KQPHMMBVFBMPPA-UHFFFAOYSA-N 0.000 claims 1
- 102000009346 Adenosine receptors Human genes 0.000 claims 1
- 108050000203 Adenosine receptors Proteins 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- QUYUZBGIPLRICV-SHTZXODSSA-N C1C[C@@H](OC)CC[C@@H]1N(C)C(=O)NC1=NC2=C(OC)C=CC(N3CCOCC3)=C2S1 Chemical compound C1C[C@@H](OC)CC[C@@H]1N(C)C(=O)NC1=NC2=C(OC)C=CC(N3CCOCC3)=C2S1 QUYUZBGIPLRICV-SHTZXODSSA-N 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 206010013654 Drug abuse Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010038687 Respiratory distress Diseases 0.000 claims 1
- 229940025084 amphetamine Drugs 0.000 claims 1
- 229940125681 anticonvulsant agent Drugs 0.000 claims 1
- 239000001961 anticonvulsive agent Substances 0.000 claims 1
- 239000000164 antipsychotic agent Substances 0.000 claims 1
- 229940005529 antipsychotics Drugs 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 229930003827 cannabinoid Natural products 0.000 claims 1
- 239000003557 cannabinoid Substances 0.000 claims 1
- 229940065144 cannabinoids Drugs 0.000 claims 1
- 239000004202 carbamide Substances 0.000 claims 1
- 229940045200 cardioprotective agent Drugs 0.000 claims 1
- 239000012659 cardioprotective agent Substances 0.000 claims 1
- 229960003920 cocaine Drugs 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 206010013663 drug dependence Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 229960004756 ethanol Drugs 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 230000007954 hypoxia Effects 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 229940035363 muscle relaxants Drugs 0.000 claims 1
- 239000003158 myorelaxant agent Substances 0.000 claims 1
- LOCJAPBORDSQSM-UHFFFAOYSA-N n-(4-methoxy-7-morpholin-4-yl-1,3-benzothiazol-2-yl)-1,4-diazabicyclo[3.2.1]octane-4-carboxamide Chemical compound C1=2SC(NC(=O)N3C4CCN(C4)CC3)=NC=2C(OC)=CC=C1N1CCOCC1 LOCJAPBORDSQSM-UHFFFAOYSA-N 0.000 claims 1
- QCLZXEPFSSSFEB-UHFFFAOYSA-N n-(4-methoxy-7-morpholin-4-yl-1,3-benzothiazol-2-yl)-4-phenylpiperazine-1-carboxamide Chemical compound C1=2SC(NC(=O)N3CCN(CC3)C=3C=CC=CC=3)=NC=2C(OC)=CC=C1N1CCOCC1 QCLZXEPFSSSFEB-UHFFFAOYSA-N 0.000 claims 1
- CDJOLCSVZMPMBZ-UHFFFAOYSA-N n-(4-methoxy-7-morpholin-4-yl-1,3-benzothiazol-2-yl)oxazepane-4-carboxamide Chemical compound C1=2SC(NC(=O)C3CNOCCC3)=NC=2C(OC)=CC=C1N1CCOCC1 CDJOLCSVZMPMBZ-UHFFFAOYSA-N 0.000 claims 1
- IASFCNWEKKVPAZ-UHFFFAOYSA-N n-(4-methoxy-7-piperidin-1-yl-1,3-benzothiazol-2-yl)-4-methyl-3-oxopiperazine-1-carboxamide Chemical compound C1=2SC(NC(=O)N3CC(=O)N(C)CC3)=NC=2C(OC)=CC=C1N1CCCCC1 IASFCNWEKKVPAZ-UHFFFAOYSA-N 0.000 claims 1
- 230000004112 neuroprotection Effects 0.000 claims 1
- 229960002715 nicotine Drugs 0.000 claims 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 1
- 229940005483 opioid analgesics Drugs 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 230000036407 pain Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- AHWALFGBDFAJAI-UHFFFAOYSA-N phenyl carbonochloridate Chemical compound ClC(=O)OC1=CC=CC=C1 AHWALFGBDFAJAI-UHFFFAOYSA-N 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 229940125723 sedative agent Drugs 0.000 claims 1
- 239000000932 sedative agent Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01129228 | 2001-12-10 | ||
| PCT/EP2002/013761 WO2003049741A1 (en) | 2001-12-10 | 2002-12-05 | Ureas of 2-aminobenzothiazoles as adenosine modulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005516006A JP2005516006A (ja) | 2005-06-02 |
| JP2005516006A5 true JP2005516006A5 (https=) | 2005-12-22 |
| JP4245483B2 JP4245483B2 (ja) | 2009-03-25 |
Family
ID=8179478
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003550790A Expired - Fee Related JP4245483B2 (ja) | 2001-12-10 | 2002-12-05 | アデノシン調節薬としての２−アミノベンゾチアゾールの尿素 |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US6727247B2 (https=) |
| EP (1) | EP1455792B1 (https=) |
| JP (1) | JP4245483B2 (https=) |
| KR (1) | KR100659793B1 (https=) |
| CN (1) | CN1602196A (https=) |
| AR (1) | AR037731A1 (https=) |
| AT (1) | ATE359792T1 (https=) |
| AU (1) | AU2002356626B2 (https=) |
| BR (1) | BR0214825A (https=) |
| CA (1) | CA2469596A1 (https=) |
| DE (1) | DE60219682T2 (https=) |
| ES (1) | ES2283652T3 (https=) |
| GT (1) | GT200200266A (https=) |
| MX (1) | MXPA04005444A (https=) |
| PA (1) | PA8559901A1 (https=) |
| PE (1) | PE20030759A1 (https=) |
| PL (1) | PL371063A1 (https=) |
| RU (1) | RU2311905C2 (https=) |
| TW (1) | TW200409628A (https=) |
| WO (1) | WO2003049741A1 (https=) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU8181701A (en) * | 2000-06-21 | 2002-01-02 | Hoffmann La Roche | Benzothiazole derivatives |
| DE60216830T2 (de) * | 2001-02-06 | 2007-06-14 | Pfizer Products Inc., Groton | Pharmazeutische Zusammensetzungen zur Behandlung von Störungen des ZNS oder anderen Erkrankungen |
| US6727247B2 (en) * | 2001-12-10 | 2004-04-27 | Hoffman-La Roche Inc. | Substituted benzothiazole amide derivatives |
| DK1522314T3 (da) * | 2002-06-26 | 2014-05-26 | Ono Pharmaceutical Co | Midler for sygdomme forårsaget af vaskulær sammentrækning eller udvidelse |
| NZ543102A (en) * | 2003-04-24 | 2008-12-24 | Incyte Corp | Aza spiro alkane derivatives as inhibitors of metalloproteases |
| JP4444290B2 (ja) * | 2003-05-19 | 2010-03-31 | エフ．ホフマン−ラ ロシュ アーゲー | アデノシン受容体リガンドとしてのベンゾチアゾール誘導体 |
| HRP20080318T3 (en) * | 2003-05-30 | 2008-07-31 | F. Hoffmann - La Roche Ag | Benzothiazole derivatives and use thereof in the treatment of diseases related to the adenosine a2a receptor |
| BRPI0414266A (pt) * | 2003-09-19 | 2006-11-07 | Hoffmann La Roche | derivados de tiazolopiridina como ligandos receptores da adenosina |
| CA2543707A1 (en) | 2003-10-31 | 2005-05-19 | Takeda Pharmaceutical Company Limited | Nitrogen-containing fused heterocyclic compounds |
| DE602004031560D1 (de) * | 2004-01-08 | 2011-04-07 | Hoffmann La Roche | Diazaspiropiperidinderivate |
| CN1956983B (zh) * | 2004-05-24 | 2010-05-26 | 弗·哈夫曼-拉罗切有限公司 | 4-羟基-4-甲基-哌啶-1-甲酸(4-甲氧基-7-吗啉-4-基-苯并噻唑-2-基)-酰胺 |
| KR100834179B1 (ko) * | 2004-05-24 | 2008-05-30 | 에프. 호프만-라 로슈 아게 | 4-하이드록시-4-메틸-피페리딘-1-카복실산(4-메톡시-7-모폴린-4-일-벤조티아졸-2-일)-아마이드 |
| EP1773795A1 (en) * | 2004-07-22 | 2007-04-18 | F.Hoffmann-La Roche Ag | Substituted benzothiazoles |
| CN1989139B (zh) * | 2004-07-22 | 2010-05-12 | 弗·哈夫曼-拉罗切有限公司 | 苯并噻唑衍生物 |
| AR055831A1 (es) | 2004-12-30 | 2007-09-12 | Janssen Pharmaceutica Nv | Pepirazinilureas y piperidinilureas como moduladores de hidrolasa de amida de acidos grasos |
| DE602006012815D1 (de) | 2005-03-23 | 2010-04-22 | Hoffmann La Roche | Acetylenylpyrazolopyrimidinderivate als mglur2-antagonsten |
| AU2006298829B2 (en) | 2005-09-27 | 2011-03-03 | F. Hoffmann-La Roche Ag | Oxadiazolyl pyrazolo-pyrimidines as mGluR2 antagonists |
| JP2009538933A (ja) | 2006-05-31 | 2009-11-12 | アボット・ラボラトリーズ | カンナビノイド受容体リガンドとしての化合物およびその使用 |
| US8841334B2 (en) | 2006-05-31 | 2014-09-23 | Abbvie Inc. | Compounds as cannabinoid receptor ligands and uses thereof |
| US7910108B2 (en) * | 2006-06-05 | 2011-03-22 | Incyte Corporation | Sheddase inhibitors combined with CD30-binding immunotherapeutics for the treatment of CD30 positive diseases |
| JP2009541354A (ja) * | 2006-06-22 | 2009-11-26 | シーブイ・セラピューティクス・インコーポレイテッド | 虚血の治療におけるａ２ａアデノシン受容体アゴニストの使用 |
| US20110172230A1 (en) * | 2006-08-23 | 2011-07-14 | Takahiro Ishii | Urea compound or salt thereof |
| CL2007003827A1 (es) * | 2006-12-28 | 2008-09-26 | Actelion Pharmaceuticals Ltd | Compuestos derivados de n-(2-aza-biciclo(3.1.0)hex-3-ilmetil)amida; y su uso para prevenir o tratar la depresion, neurosis, esquizofrenia, ansiedad, adicciones, epilepsia, dolor, enfermedades cardiacas, entre otras. |
| CA2681586A1 (en) | 2007-03-28 | 2008-10-09 | Abbott Laboratories | 1, 3-thiazol-2 (3h) -ylidene compounds as cannabinoid receptor ligands |
| US7872033B2 (en) | 2007-04-17 | 2011-01-18 | Abbott Laboratories | Compounds as cannabinoid receptor ligands |
| EP2160393A1 (en) | 2007-05-18 | 2010-03-10 | Abbott Laboratories | Novel compounds as cannabinoid receptor ligands |
| AU2008263166A1 (en) * | 2007-05-25 | 2008-12-18 | Janssen Pharmaceutica N.V. | Heteroaryl-substituted urea modulators of fatty acid amide hydrolase |
| US8455520B2 (en) | 2007-07-17 | 2013-06-04 | Merck Sharp & Dohme Corp. | Soluble epoxide hydrolase inhibitors, compositions containing such compounds and methods of treatment |
| US9193713B2 (en) | 2007-10-12 | 2015-11-24 | Abbvie Inc. | Compounds as cannabinoid receptor ligands |
| US9226907B2 (en) | 2008-02-01 | 2016-01-05 | Abbvie Inc. | Extended release hydrocodone acetaminophen and related methods and uses thereof |
| US8846730B2 (en) | 2008-09-08 | 2014-09-30 | Abbvie Inc. | Compounds as cannabinoid receptor ligands |
| EP2334646A2 (en) | 2008-09-16 | 2011-06-22 | Abbott Laboratories | Substituted benzamides as cannabinoid receptor ligands |
| US8598356B2 (en) * | 2008-11-25 | 2013-12-03 | Janssen Pharmaceutica Nv | Heteroaryl-substituted urea modulators of fatty acid amide hydrolase |
| US8461159B2 (en) | 2008-11-25 | 2013-06-11 | Jannsen Pharmaceutica BV | Heteroaryl-substituted urea modulators of fatty acid amide hydrolase |
| PA8854001A1 (es) | 2008-12-16 | 2010-07-27 | Abbott Lab | Compuestos novedosos como ligandos de receptores de canabinoides |
| FR2945531A1 (fr) * | 2009-05-12 | 2010-11-19 | Sanofi Aventis | Derives de 7-aza-spiro°3,5!nonane-7-carboxylates, leur preparation et leur application en therapeutique |
| WO2010141809A1 (en) | 2009-06-05 | 2010-12-09 | Janssen Pharmaceutica Nv | Aryl-substituted heterocyclic urea modulators of fatty acid amide hydrolase |
| WO2010141817A1 (en) | 2009-06-05 | 2010-12-09 | Janssen Pharmaceutica Nv | Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase |
| WO2011021645A1 (ja) * | 2009-08-19 | 2011-02-24 | 大日本住友製薬株式会社 | ２環性ウレア誘導体、またはその薬学的に許容される塩 |
| UA108233C2 (uk) | 2010-05-03 | 2015-04-10 | Модулятори активності гідролази амідів жирних кислот | |
| US9605002B2 (en) * | 2012-07-18 | 2017-03-28 | University Of Notre Dame Du Lac | 5,5-heteroaromatic anti-infective compounds |
| EP2991967A1 (en) * | 2013-03-20 | 2016-03-09 | F. Hoffmann-La Roche AG | Urea derivatives and their use as fatty-acid binding protein (fabp) inhibitors |
| CN105164104B (zh) * | 2013-03-20 | 2019-04-12 | 豪夫迈·罗氏有限公司 | 脲衍生物及其作为脂肪酸结合蛋白(fabp)抑制剂的用途 |
| US11970486B2 (en) * | 2016-10-24 | 2024-04-30 | Janssen Pharmaceutica Nv | Compounds and uses thereof |
| EA201991650A1 (ru) | 2017-01-06 | 2020-01-20 | Юманити Терапьютикс, Инк. | Способы лечения неврологических расстройств |
| CA3083000A1 (en) | 2017-10-24 | 2019-05-02 | Yumanity Therapeutics, Inc. | Compounds and uses thereof |
| WO2019141096A1 (zh) * | 2018-01-19 | 2019-07-25 | 四川科伦博泰生物医药股份有限公司 | 取代脲类化合物及其制备方法和用途 |
| BR112020019191A2 (pt) | 2018-03-23 | 2021-01-05 | Yumanity Therapeutics, Inc. | Compostos e seus usos |
| CN111205244B (zh) * | 2018-11-22 | 2023-08-18 | 上海科技大学 | 噻唑并环类化合物、其制备方法、中间体和应用 |
| MX2021008903A (es) | 2019-01-24 | 2021-11-04 | Yumanity Therapeutics Inc | Compuestos y usos de los mismos. |
| EA202192047A1 (ru) | 2019-11-13 | 2021-12-08 | Юманити Терапьютикс, Инк. | Соединения и их применение |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US45615A (en) * | 1864-12-27 | Improvement in cultivators | ||
| US3954766A (en) * | 1975-07-09 | 1976-05-04 | Stanford Research Institute | 1,4-Diazabicyclo[3.2.1]octanes |
| DE3374550D1 (en) | 1982-12-21 | 1987-12-23 | Johnsen Jorgensen Plastics Ltd | Dispensing container |
| DE4241013A1 (de) * | 1992-12-05 | 1994-06-09 | Boehringer Ingelheim Kg | Verwendung von 2-Amino-6-n-propyl-amino-4,5,6,7-tetrahydrobenzothiazol als Arzneimittel mit antidepressiver Wirkung |
| JP2003521543A (ja) | 2000-02-07 | 2003-07-15 | アボット ゲーエムベーハー ウント カンパニー カーゲー | ２−ベンゾチアゾリル尿素誘導体およびそのプロテインキナーゼ阻害剤としての使用 |
| AU8181701A (en) * | 2000-06-21 | 2002-01-02 | Hoffmann La Roche | Benzothiazole derivatives |
| US6599901B1 (en) * | 2001-11-19 | 2003-07-29 | Hoffman-La Roche Inc. | Pyridone substituted benzothiazole derivatives |
| US6727247B2 (en) * | 2001-12-10 | 2004-04-27 | Hoffman-La Roche Inc. | Substituted benzothiazole amide derivatives |
-
2002
- 2002-12-03 US US10/308,338 patent/US6727247B2/en not_active Expired - Fee Related
- 2002-12-05 KR KR1020047008868A patent/KR100659793B1/ko not_active Expired - Fee Related
- 2002-12-05 PL PL02371063A patent/PL371063A1/xx not_active Application Discontinuation
- 2002-12-05 CN CNA028246543A patent/CN1602196A/zh active Pending
- 2002-12-05 TW TW091135281A patent/TW200409628A/zh unknown
- 2002-12-05 WO PCT/EP2002/013761 patent/WO2003049741A1/en not_active Ceased
- 2002-12-05 JP JP2003550790A patent/JP4245483B2/ja not_active Expired - Fee Related
- 2002-12-05 ES ES02804578T patent/ES2283652T3/es not_active Expired - Lifetime
- 2002-12-05 MX MXPA04005444A patent/MXPA04005444A/es active IP Right Grant
- 2002-12-05 BR BR0214825-0A patent/BR0214825A/pt not_active Application Discontinuation
- 2002-12-05 DE DE60219682T patent/DE60219682T2/de not_active Expired - Lifetime
- 2002-12-05 PA PA20028559901A patent/PA8559901A1/es unknown
- 2002-12-05 PE PE2002001174A patent/PE20030759A1/es not_active Application Discontinuation
- 2002-12-05 AT AT02804578T patent/ATE359792T1/de active
- 2002-12-05 EP EP02804578A patent/EP1455792B1/en not_active Expired - Lifetime
- 2002-12-05 CA CA002469596A patent/CA2469596A1/en not_active Abandoned
- 2002-12-05 RU RU2004121166/15A patent/RU2311905C2/ru not_active IP Right Cessation
- 2002-12-05 AU AU2002356626A patent/AU2002356626B2/en not_active Ceased
- 2002-12-06 AR ARP020104739A patent/AR037731A1/es unknown
- 2002-12-09 GT GT200200266A patent/GT200200266A/es unknown
-
2003
- 2003-10-23 US US10/691,770 patent/US7019001B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005516006A5 (https=) | ||
| RU2004121166A (ru) | 2-аминобензотиазолилмочевины в качестве модуляторов аденозина | |
| CN100415716C (zh) | 1－(1，2－双取代哌啶基)－4－取代哌嗪衍生物 | |
| US11033539B2 (en) | Compounds of formulas (VII), (VIII), (IX), (XI), (XII), (XIII), and (XIV) as muscarinic receptor 4(M4) antagonists for treating neurological diseases | |
| CN1131854C (zh) | 作为速激肽受体拮抗剂的1－(1,2－二取代哌啶基)－4－取代哌啶衍生物 | |
| JP5829644B2 (ja) | Ｓｙｋ阻害剤としてのアミノピリミジン類 | |
| JP6014149B2 (ja) | ヤヌスキナーゼ阻害剤としての非環式シアノエチルピラゾール | |
| CN1134431C (zh) | 作为多巴胺d4受体拮抗剂的2,4-二氨基嘧啶衍生物 | |
| JP4244189B2 (ja) | アデノシン受容体リガンドとしての７−アミノ−ベンゾチアゾール誘導体 | |
| JP2006521345A (ja) | ニコチン性アセチルコリン受容体の正のアロステリック調節剤 | |
| CN1066733C (zh) | 1－(1,2－二取代哌啶基)－4－(稠合咪唑)哌啶衍生物 | |
| AU2004222341A1 (en) | Tetrahydropyranyl cyclopentyl heterocylic amide modulators of chemokine receptor activity | |
| JP2010504323A (ja) | Ｉｖ型ホスホジエステラーゼの阻害物質 | |
| CN1117090C (zh) | 作为速激肽拮抗剂的n－酰基－2－取代的－4－(苯并咪唑基或咪唑并吡啶基取代的残基)哌啶 | |
| JP2009513491A (ja) | 新規な８−アザ−ビシクロ［３．２．１］オクタン誘導体、及びモノアミン神経伝達物質の再取り込み阻害剤としてのその使用 | |
| JP2005537297A (ja) | アルファ−７ｎａｃｈｒ活性を有する１ｈ−ピラゾールおよび１ｈ−ピロール−アザビシクロ化合物 | |
| CN1938291A (zh) | 被取代的4－烷基－和4－烷酰基－哌啶衍生物和其作为神经激肽拮抗剂的用途 | |
| JP5080450B2 (ja) | 新規なピペリジン置換インドール | |
| US20070238723A1 (en) | Benzoxazinyl-amidocyclopentyl-heterocyclic modulators of chemokine receptors | |
| KR20230035349A (ko) | 수면 무호흡의 치료를 위한 알파2-아드레날린수용체 하위유형 c (알파-2c) 길항제와 task1/3 채널 차단제의 조합물 | |
| WO2025207539A1 (en) | Sarm1 inhibitors | |
| KR101049075B1 (ko) | 치환된 1-피페리딘-3-일-4-피페리딘-4-일-피페라진 유도체및 그의 뉴로키닌 길항제로서의 용도 | |
| JP2008521771A (ja) | 改良された抗精神病活性および抗不安症活性を有するイソキサゾリン−インドール誘導体 | |
| JPWO2001027104A1 (ja) | 置換イミダゾリジノン誘導体 | |
| EA039638B1 (ru) | Антагонисты мускаринового рецептора 4 и способы их применения |